MMV533

Translational

-

Human volunteers

(Sanofi)

Asexual blood stages

Uncomplicated malaria treatments and resistance management (TPP-1)

Product vision	Uncomplicated malaria and resistance management
MOA	Unknown, inability to select resistance mutants
Key features	Rapid parasite killing in vitro and clearance in induced blood-stage malaria study Long half-life in human volunteers Predicted human low single dose. Non-teratogenic: Potential for use in pregnancy
Status	First-in-human and volunteer infection study ongoing
Next milestone	Identification of a combination partner Start phase II clinical study
Previously	Discovery collaboration between MMV and Sanofi, SAR 441121 Full reference name is MMV688533
Project Director	Dr Benoît Bestgen